The silicone segment by type is estimated to lead the market growth during the forecast period.
According to a new market research study of “Asia Pacific Biopharmaceutical Tubing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Type, Application and Country.” The Asia Pacific biopharmaceutical tubing market is expected to reach US$ 903.19 million by 2028 from US$ 487.50 million in 2021; it is estimated to grow at a CAGR of 9.2% from 2021 to 2028. The report highlights trends prevailing in the Asia Pacific biopharmaceutical tubing market and the factors driving market along with those that act as hindrances. The growth of the market is attributed to key factors such as increasing elderly population in world and proliferation of healthcare sector in developing economies. However, stringent regulatory framework by government for biopharmaceutical applications is expected to restrict the market growth during the forecast period.
Popularity of minimally invasive surgical procedures has increased in the recent years owing to the benefits such as tiny incisions, faster recovery of patients, and less discomfort caused to the patients. The growing prevalence of arthritis, cancer, and cardiovascular diseases, all of which require extensive surgical treatments, has boosted the demand for minimally invasive procedures. As a result, there is an enormous demand for catheters and biopharmaceutical tubing, among other components. Further, biopharmaceutical tubing systems are reasonably priced and aid in time-saving procedures. For example, employing catheter tubing for cardiac and urine catheterization significantly lowers the time required for the medical or surgical operation. Therefore, the growing demand for minimally invasive medical procedures and focus on increasing the efficiency of these procedures play an important role in propelling the demand for biopharmaceutical tubing. The healthcare sectors in Asia Pacific countries as well as other developing economies is projected to expand rapidly in the near future, and the projected growth can be ascribed to changes in customer demand, increase in awareness about healthcare services, and continuity of aging population. Thus, growing prevalence of chronic diseases is compelling people to seek medical assistance, which, in turn is increasing the demand for catheters and biopharmaceutical tubing in the healthcare sector. Further, greater government spending on healthcare facilities and increased consumer purchasing power are also likely to contribute to the growth of the healthcare sector, as well as the biopharmaceutical tubing market.
Countries in Asia Pacific are facing challenges due to increasing incidences of COVID-19. Increasing usage in a wide range of applications such as drug delivery, catheter & cannulas, and bulk disposable tubing has increased the demand for the biopharmaceutical tubing market. However, due to the impact of pandemic, the medical device industry has experienced both ups and downs and witnessed increased demand for critical pieces of equipment such as ventilators and respiratory devices. While the COVID-19 has caused unprecedented disruption, it has also created opportunities for the region's pharmaceutical and medical device sectors. Many companies have also extended their operations in the region to overcome supply chain hindrance. Hence, COVID-19 pandemic has a positive influence on Asia Pacific biopharmaceutical tubing market growth.
The Asia Pacific biopharmaceutical tubing market, by type, is segmented into plastic, metal, and silicone. Based on application, the Asia Pacific biopharmaceutical tubing market is segmented into pharmaceutical, medical devices, research and development, and others. Geographically, Asia Pacific biopharmaceutical tubing market can be sub-segmented into China, Japan, India, Australia, South Korea and Rest of Asia Pacific.
W. L. Gore and Associates, Inc. Saint-Gobain Sekurit, Freudenberg Group, RAUMEDIC AG, TEKNI-PLEX, NewAge Industries, Inc, Optinova, Zeus Industrial Products, Inc. NORDSON CORPORATION and DuPont de Nemours, Inc. are among the leading companies operating in the Asia Pacific biopharmaceutical tubing market
According to a new market research study of “Asia Pacific Biopharmaceutical Tubing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Type, Application and Country.” The Asia Pacific biopharmaceutical tubing market is expected to reach US$ 903.19 million by 2028 from US$ 487.50 million in 2021; it is estimated to grow at a CAGR of 9.2% from 2021 to 2028. The report highlights trends prevailing in the Asia Pacific biopharmaceutical tubing market and the factors driving market along with those that act as hindrances. The growth of the market is attributed to key factors such as increasing elderly population in world and proliferation of healthcare sector in developing economies. However, stringent regulatory framework by government for biopharmaceutical applications is expected to restrict the market growth during the forecast period.
Popularity of minimally invasive surgical procedures has increased in the recent years owing to the benefits such as tiny incisions, faster recovery of patients, and less discomfort caused to the patients. The growing prevalence of arthritis, cancer, and cardiovascular diseases, all of which require extensive surgical treatments, has boosted the demand for minimally invasive procedures. As a result, there is an enormous demand for catheters and biopharmaceutical tubing, among other components. Further, biopharmaceutical tubing systems are reasonably priced and aid in time-saving procedures. For example, employing catheter tubing for cardiac and urine catheterization significantly lowers the time required for the medical or surgical operation. Therefore, the growing demand for minimally invasive medical procedures and focus on increasing the efficiency of these procedures play an important role in propelling the demand for biopharmaceutical tubing. The healthcare sectors in Asia Pacific countries as well as other developing economies is projected to expand rapidly in the near future, and the projected growth can be ascribed to changes in customer demand, increase in awareness about healthcare services, and continuity of aging population. Thus, growing prevalence of chronic diseases is compelling people to seek medical assistance, which, in turn is increasing the demand for catheters and biopharmaceutical tubing in the healthcare sector. Further, greater government spending on healthcare facilities and increased consumer purchasing power are also likely to contribute to the growth of the healthcare sector, as well as the biopharmaceutical tubing market.
Countries in Asia Pacific are facing challenges due to increasing incidences of COVID-19. Increasing usage in a wide range of applications such as drug delivery, catheter & cannulas, and bulk disposable tubing has increased the demand for the biopharmaceutical tubing market. However, due to the impact of pandemic, the medical device industry has experienced both ups and downs and witnessed increased demand for critical pieces of equipment such as ventilators and respiratory devices. While the COVID-19 has caused unprecedented disruption, it has also created opportunities for the region's pharmaceutical and medical device sectors. Many companies have also extended their operations in the region to overcome supply chain hindrance. Hence, COVID-19 pandemic has a positive influence on Asia Pacific biopharmaceutical tubing market growth.
The Asia Pacific biopharmaceutical tubing market, by type, is segmented into plastic, metal, and silicone. Based on application, the Asia Pacific biopharmaceutical tubing market is segmented into pharmaceutical, medical devices, research and development, and others. Geographically, Asia Pacific biopharmaceutical tubing market can be sub-segmented into China, Japan, India, Australia, South Korea and Rest of Asia Pacific.
W. L. Gore and Associates, Inc. Saint-Gobain Sekurit, Freudenberg Group, RAUMEDIC AG, TEKNI-PLEX, NewAge Industries, Inc, Optinova, Zeus Industrial Products, Inc. NORDSON CORPORATION and DuPont de Nemours, Inc. are among the leading companies operating in the Asia Pacific biopharmaceutical tubing market
Reasons to buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific biopharmaceutical tubing market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific biopharmaceutical tubing market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
3. Research Methodology
4. Asia Pacific Biopharmaceutical Tubing Market - Market Landscape
5. Biopharmaceutical Tubing Market - Key Market Dynamics
6. Biopharmaceutical Tubing Market - Asia Pacific Analysis
7. Biopharmaceutical Tubing Market Analysis - By Type
8. Biopharmaceutical Tubing Market Analysis - By Application
9. Biopharmaceutical Tubing Market - Asia Pacific Analysis
10. Impact of COVID-19 Pandemic on Asia Pacific Biopharmaceutical Tubing Market
11. Biopharmaceutical Tubing Market - Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned
- W. L. Gore and Associates, Inc.
- Saint-Gobain Sekurit
- Freudenberg Group
- RAUMEDIC AG
- TEKNI-PLEX
- NewAge Industries, Inc
- Optinova
- Zeus Industrial Products, Inc.
- Nordson Corporation
- DuPont de Nemours, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 125 |
Published | August 2021 |
Forecast Period | 2021 - 2028 |
Estimated Market Value ( USD | $ 487.5 Million |
Forecasted Market Value ( USD | $ 903.19 Million |
Compound Annual Growth Rate | 9.2% |
Regions Covered | Asia Pacific |
No. of Companies Mentioned | 10 |